Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

Reversal of novel oral anticoagulants in patients with major bleeding.

Siegal DM, Cuker A.

J Thromb Thrombolysis. 2013 Apr;35(3):391-8. doi: 10.1007/s11239-013-0885-0. Review.

PMID:
23389753
2.

Bleeding and antidotes in new oral anticoagulants.

Majeed A, Schulman S.

Best Pract Res Clin Haematol. 2013 Jun;26(2):191-202. doi: 10.1016/j.beha.2013.07.001. Epub 2013 Jul 21. Review.

PMID:
23953907
3.

How I treat target-specific oral anticoagulant-associated bleeding.

Siegal DM, Garcia DA, Crowther MA.

Blood. 2014 Feb 20;123(8):1152-8. doi: 10.1182/blood-2013-09-529784. Epub 2014 Jan 2.

4.

Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.

Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, Rosencher N, Schved JF, de Maistre E, Samama MM, Mismetti P, Sié P; Working Group on Perioperative Haemostasis.

Arch Cardiovasc Dis. 2013 Jun-Jul;106(6-7):382-93. doi: 10.1016/j.acvd.2013.04.009. Epub 2013 Jun 25.

5.

Newer clinically available antithrombotics and their antidotes.

Lévy S.

J Interv Card Electrophysiol. 2014 Sep;40(3):269-75. doi: 10.1007/s10840-014-9910-2. Epub 2014 Jun 18. Review.

PMID:
24934756
6.

Pharmacologic interventions for reversing the effects of oral anticoagulants.

Kalus JS.

Am J Health Syst Pharm. 2013 May 15;70(10 Suppl 1):S12-21. doi: 10.2146/ajhp130041.

PMID:
23640528
7.

Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents.

Siegal DM.

J Thromb Thrombolysis. 2015 Apr;39(3):395-402. doi: 10.1007/s11239-015-1167-9. Review.

PMID:
25586208
8.

Specific antidotes in development for reversal of novel anticoagulants: a review.

Gomez-Outes A, Suarez-Gea ML, Lecumberri R, Terleira-Fernandez AI, Vargas-Castrillon E.

Recent Pat Cardiovasc Drug Discov. 2014;9(1):2-10. Review.

PMID:
25494843
9.

Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.

Sarode R, Milling TJ Jr, Refaai MA, Mangione A, Schneider A, Durn BL, Goldstein JN.

Circulation. 2013 Sep 10;128(11):1234-43. doi: 10.1161/CIRCULATIONAHA.113.002283. Epub 2013 Aug 9.

10.

Risk of thromboembolic events after protocolized warfarin reversal with 3-factor PCC and factor VIIa.

Barton CA, Johnson NB, Case J, Warden B, Hughes D, Zimmerman J, Roberti G, McMillian WD, Schreiber M.

Am J Emerg Med. 2015 Nov;33(11):1562-6. doi: 10.1016/j.ajem.2015.06.010. Epub 2015 Jun 12.

PMID:
26143317
11.

New oral anticoagulants in the treatment of acute venous thromboembolism - a systematic review with indirect comparisons.

Hirschl M, Kundi M.

Vasa. 2014 Sep;43(5):353-64. doi: 10.1024/0301-1526/a000373. Review. Erratum in: Vasa. 2014 Nov;43(6):477.

PMID:
25147012
12.

Current state of knowledge on oral anticoagulant reversal using procoagulant factors.

Nitzki-George D, Wozniak I, Caprini JA.

Ann Pharmacother. 2013 Jun;47(6):841-55. doi: 10.1345/aph.1R724. Epub 2013 May 21. Review.

PMID:
23695644
13.

Antidotes to non-vitamin K oral anticoagulants: necessary or not?

Proietti M, Lip GY.

Expert Opin Pharmacother. 2015;16(11):1573-6. doi: 10.1517/14656566.2015.1057119. Epub 2015 Jun 16. Review.

PMID:
26077323
14.

Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates.

Baumann Kreuziger LM, Keenan JC, Morton CT, Dries DJ.

Biomed Res Int. 2014;2014:583794. doi: 10.1155/2014/583794. Epub 2014 Jul 20. Review.

15.

Treatment of bleeding complications when using oral anticoagulants for prevention of strokes.

Akwaa F, Spyropoulos AC.

Curr Treat Options Cardiovasc Med. 2013 Jun;15(3):288-98. doi: 10.1007/s11936-013-0238-5.

PMID:
23494907
16.

Reversal of target-specific oral anticoagulants.

Siegal DM, Cuker A.

Drug Discov Today. 2014 Sep;19(9):1465-70. doi: 10.1016/j.drudis.2014.05.013. Epub 2014 May 29. Review.

17.

Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.

[No authors listed]

Prescrire Int. 2013 Jun;22(139):155-9. Review.

PMID:
23866358
18.

Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants.

Liew A, Eikelboom JW, O'Donnell M, Hart RG.

Can J Cardiol. 2013 Jul;29(7 Suppl):S34-44. doi: 10.1016/j.cjca.2013.04.013. Review.

PMID:
23790596
19.

Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.

Perzborn E, Heitmeier S, Laux V, Buchmüller A.

Thromb Res. 2014 Apr;133(4):671-81. doi: 10.1016/j.thromres.2014.01.017. Epub 2014 Jan 21.

20.

Reversal of antithrombotic agents.

Bauer KA.

Am J Hematol. 2012 May;87 Suppl 1:S119-26. doi: 10.1002/ajh.23165. Epub 2012 Mar 28. Review.

Items per page

Supplemental Content

Write to the Help Desk